Breaking News

Briakinumab is safe and efficacious in phase II and III trials in psoriasis

Briakinumab is safe and efficacious in phase II and III trials in psoriasis

 
 

Data from two clinical studies of briakinumab (ABT-874; Abbott), a fully human monoclonal antibody designed to target and neutralize interleukin-12 (IL-12) and IL-23 for the treatment of patients with moderate to severe psoriasis, were recently presented at the Summer Meeting of the American Academy of Dermatology held in Chicago. A 12-week, randomized, double-blind, placebo-controlled, phase II trial evaluated the safety and efficacy of subcutaneous injections of briakinumab versus placebo in 180 subjects with psoriasis affecting > 10% of their body surface area and exhibiting a Psoriasis Area and Severity Index (PASI) score >= 12 (ClinicalTrials.gov Identifier NCT00292396). Briakinumab was administered at five treatment schedules: a single 200-mg dose at week 0, 100 mg ...

 
to Continue Reading, Login Now
 

Please Login

 
 
  
 
 
If you are a registered user but you have forgotten your password, please click here
 
If you are not a registered user, please register here

return to breaking news list